NCT02462967COMPLETEDanonymous

A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Sponsor

Source record

Galectin Therapeutics Inc.

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Galectin-3, a carbohydrate-binding protein involved in fibrosis and inflammation.

Indication / condition

AI-normalized

Hypertension, Portal

Intervention

Source record

GR-MD-02, Placebo

Source & freshness

Source record

NCT ID

NCT02462967

Original source

ClinicalTrials.gov

Source last updated

Oct 08, 2020

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT02462967

Title

A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Sponsor

Galectin Therapeutics Inc.

Status

COMPLETED

Phase

Phase 2

Condition raw

Hypertension, Portal

Condition normalized

Hypertension, Portal

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Galectin-3, a carbohydrate-binding protein involved in fibrosis and inflammation.

Target normalized

Galectin-3, a carbohydrate-binding protein involved in fibrosis and inflammation.

Interventions

GR-MD-02, Placebo

Public preview

Source record

Galectin Therapeutics Inc. is advancing GR-MD-02, a novel therapeutic targeting liver fibrosis and portal hypertension associated with NASH cirrhosis. The Phase 2 trial's completion indicates progress towards potential market entry in a growing sector, as NASH-related liver diseases are increasingly recognized. The competitive landscape includes other fibrosis-targeting therapies, necessitating a robust differentiation strategy. Diligence should focus on the safety profile and efficacy outcomes to assess market viability and potential partnerships or acquisition interest.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02462967

Status

COMPLETED

Phase

Phase 2

Sponsor

Galectin Therapeutics Inc.

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedOct 08, 2020

Internal syncJun 09, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02462967

Indication

Hypertension, Portal

Modality

small molecule

Target

Galectin-3, a carbohydrate-binding protein involved in fibrosis and inflammation.

Intervention

GR-MD-02, Placebo

Source record